Longevity capital spans aging-biology specialists, therapeutic company builders and adjacent preventive-health technology investors. These 15 routes separate scientific development from broad healthy-aging marketing.
Use this list to build a focused research queue. Start with your company’s stage, the evidence you have and the milestone the round should finance. Then choose a small set of relevant providers, confirm the current mandate and plan an appropriate first conversation.
Longevity and healthspan capital at a glance
This is a selective, unranked directory of 15 provider families. A venture fund, angel network, co-investor and growth or strategic investor can serve different company needs. The scope column records geographic, institutional or investment-stage context, not a claim that every organization is headquartered locally.
| Provider | Capital route | Investment scope |
|---|---|---|
| age1 | Longevity biotechnology venture firm | Healthy-lifespan biotechnology |
| Apollo Health Ventures | Life-sciences venture builder and investor | Aging biology and age-related disease |
| LongeVC | Biotechnology venture firm | Therapeutics, diagnostics and longevity infrastructure |
| Healthspan Capital | Early-stage longevity biotechnology fund | LongBio and regenerative medicine |
| Kizoo Technology Capital | Rejuvenation-biotechnology investor | Companies addressing age-related biological mechanisms |
| Korify Capital | Biotechnology investment firm | Science-based healthspan and related biotechnology |
| Centenara Labs | Therapeutics company builder and investor | Geriatric diseases and healthspan research |
| Maximon | Longevity company builder | Science-based healthy-aging businesses |
| R42 Group | Deep-science investment and invention platform | AI, biotechnology and longevity |
| Lifespan Vision Ventures | Early-stage longevity venture firm | Aging biology, age-related disease and enabling technologies |
| Continuum Health Ventures | Early-stage health-technology venture firm | Healthtech, techbio and healthspan |
| Immortal Dragons | Purpose-driven longevity investment firm | Longevity biotechnology and supporting infrastructure |
| ARCH Venture Partners | Science-driven venture firm | Transformative biotechnology company creation |
| Future Ventures | Seed and early-stage technology venture firm | Frontier science and company creation |
| LifeX Ventures | Health and AI venture firm | Preventive health and enabling health technology |
Match scientific evidence to the type of investor
- State whether the company develops a therapeutic, diagnostic, enabling platform or health-software product.
- Separate a biological hypothesis from replicated preclinical or clinical evidence.
- Match company-building, seed development and later operating needs to the appropriate capital route.
Illustrative example: an aging-biology startup has replicated cell-model results but no human efficacy evidence. It prepares a controlled next-study plan for biotechnology specialists. It does not describe the research as a proven anti-aging treatment or pitch the same program as preventive-health software.
Avoid this shortcut: A longevity conference, consumer supplement brand and biotechnology venture fund are different organizations and search intents.
15 providers to research
1. age1
Longevity biotechnology venture firm. Healthy-lifespan biotechnology.
age1 explicitly funds longevity companies and describes supporting founders building rigorous biotechnology businesses. age1 official information.
Prepare before outreach: Explain the scientific hypothesis, reproducible evidence and next development milestone. Do not count predecessor Longevity Fund as another investor.
2. Apollo Health Ventures
Life-sciences venture builder and investor. Aging biology and age-related disease.
Apollo describes building and investing in companies targeting age-related diseases and aging biology. Apollo Health Ventures official information.
Prepare before outreach: Prepare a clear research-to-company plan and clarify whether the opportunity fits company creation or external investment.
3. LongeVC
Biotechnology venture firm. Therapeutics, diagnostics and longevity infrastructure.
LongeVC explicitly includes aging mechanisms, diagnostics and enabling biotechnology platforms in its investment focus. LongeVC official information.
Prepare before outreach: Identify the development stage and evidence package, separating therapeutic claims from what experiments have actually demonstrated.
4. Healthspan Capital
Early-stage longevity biotechnology fund. LongBio and regenerative medicine.
Healthspan describes investing in early longevity-biotechnology and regenerative-medicine companies. Healthspan Capital official information.
Prepare before outreach: Ask about current company-investment appetite. Its notice about fund subscriptions is not evidence that any particular startup is eligible.
5. Kizoo Technology Capital
Rejuvenation-biotechnology investor. Companies addressing age-related biological mechanisms.
Kizoo publishes a rejuvenation-biotechnology focus and a portfolio of related therapeutic-development companies. Kizoo Technology Capital official information.
Prepare before outreach: Explain the target mechanism, experimental controls and next validation step without claiming a treatment already works in people.
6. Korify Capital
Biotechnology investment firm. Science-based healthspan and related biotechnology.
Korify's current portfolio includes Cambrian and Refoxy, described in relation to healthspan and age-related disease research. Korify Capital official information.
Prepare before outreach: Use the named portfolio as evidence of relevant experience and clarify present mandate and development-stage fit.
7. Centenara Labs
Therapeutics company builder and investor. Geriatric diseases and healthspan research.
Centenara, the current identity reached from Rejuveron, describes founding or investing in early therapeutics companies. Centenara Labs official information.
Prepare before outreach: Treat this as a company-building or strategic investment route, not an unrestricted general-purpose VC application.
8. Maximon
Longevity company builder. Science-based healthy-aging businesses.
Maximon describes building and backing science-based companies developing healthy-aging and rejuvenation solutions. Maximon official information.
Prepare before outreach: Clarify the company-building model, founder responsibilities and capital arrangement before comparing it with a conventional fund.
9. R42 Group
Deep-science investment and invention platform. AI, biotechnology and longevity.
R42 describes inventing and financing deep-science ventures from pre-seed company invention through growth. R42 Group official information.
Prepare before outreach: Select the investment lane rather than an education event, and explain the scientific and company-building support required.
10. Lifespan Vision Ventures
Early-stage longevity venture firm. Aging biology, age-related disease and enabling technologies.
Lifespan Vision explicitly targets pre-seed, seed and Series A companies addressing aging and age-related disease. Lifespan Vision Ventures official information.
Prepare before outreach: Map the evidence to a defined modality or platform and distinguish the near-term indication from a broader longevity hypothesis.
11. Continuum Health Ventures
Early-stage health-technology venture firm. Healthtech, techbio and healthspan.
Continuum explicitly describes an early investment focus spanning health technology, techbio and healthspan extension. Continuum Health Ventures official information.
Prepare before outreach: Explain whether the product is software, a research platform or a therapeutic program so the investor can assess the appropriate evidence.
12. Immortal Dragons
Purpose-driven longevity investment firm. Longevity biotechnology and supporting infrastructure.
Immortal Dragons publishes a company portfolio spanning regenerative and genetic-medicine approaches, as well as separate fund and ecosystem activity. Immortal Dragons official information.
Prepare before outreach: Use the direct-company route and explain the scientific objective; grants, sponsorships and fund allocations are different decisions.
13. ARCH Venture Partners
Science-driven venture firm. Transformative biotechnology company creation.
ARCH's current portfolio includes Altos Labs, described in relation to cellular resilience and rejuvenation. ARCH Venture Partners official information.
Prepare before outreach: Bring a defensible scientific program and company-creation rationale; ARCH is broader than longevity and not every biology project fits.
14. Future Ventures
Seed and early-stage technology venture firm. Frontier science and company creation.
Future's current materials identify women's reproductive longevity among the scientific areas its team has backed. Future Ventures official information.
Prepare before outreach: Explain the technical thesis and commercial development plan, then confirm current partner and company-stage fit.
15. LifeX Ventures
Health and AI venture firm. Preventive health and enabling health technology.
LifeX's current portfolio includes Function Health and other preventive or enabling health-technology companies. LifeX Ventures official information.
Prepare before outreach: Treat this as an adjacent health-technology lane, not a claim that LifeX funds every aging-biology drug program.
Turn the directory into your next five research actions
Choose five providers with a plausible mandate match, not five familiar logos. For each one, keep a source and one unresolved fit question beside the next action. Leave unknown information blank until you can verify it.
A compact investor-fit worksheet
Copy one record per provider. Replace the bracketed fields with company-specific evidence.
Longevity and healthspan investor research
Provider: [name and specific fund]
Official source + checked date: [URL, date]
Why our stage and technology fit: [evidence]
Geographic or institutional connection: [evidence]
Milestone this round finances: [specific result]
Open fit question: [one question]
Introduction or founder route: [verified route]
Therapeutic, platform or software lane: [evidence or unknown]
Evidence level and limitations: [evidence or unknown]
Next independently testable milestone: [evidence or unknown]
Owner + next action + date: [person, action, date]
Decision: [research next / ask a question / hold]Move a provider forward when the current mandate and your company evidence match. Ask a question when one material criterion is unclear. Hold when the fund is at the wrong stage, serves a different company geography or expects evidence you do not yet have. Do not treat a contact record as investor interest.
Give Aurora, Claude or Codex a focused research mission
Use this prompt with Aurora in Finta, Claude or Codex. Add only material you are authorized to share. Review the result before adding records or contacting anyone.
Be my Longevity and healthspan investor-research teammate.
Company: [one sentence, stage and location]
Technology or business model: [specific scope]
Evidence we have: [authorized facts only]
Next financing milestone: [result to fund]
Focus checks: Therapeutic, platform or software lane; Evidence level and limitations; Next independently testable milestone
Candidates: [paste five provider names from this guide]
Check each provider's current official sources.
Return: fit evidence, source URL/date, one open question, next action.
Separate local presence, investment reach and eligibility.
Mark missing facts unknown; do not invent cheque sizes or contacts.
Check portfolio conflicts before suggesting sensitive material.
Draft a research queue only. Do not contact or submit to anyone.Keep the next step moving
A useful shortlist connects investor fit to a relationship owner and a specific next action. Use Finta’s investor-prospecting workflow to organize the research. Keep the official source, contact context and follow-up together in your fundraising pipeline.
Before asking for an introduction, review portfolio conflicts and prepare a relevant message. The warm-introduction guide explains how to make a clear, permission-aware request. A possible path is not a completed introduction or a financing commitment.
Related research: Broader biotech investors
A common founder question
Does a listed investment prove the underlying treatment works?
No. Investment is not clinical validation. This directory concerns capital research, not medical advice, therapeutic efficacy or expected investment returns.
How this list was researched
Research reviewed on October 29, 2026 using the linked official investment, portfolio and program pages. We count related firms and vehicles as one provider family where noted. Order is not a performance ranking. Public mandate evidence does not establish uncommitted capital, an open application window or an offer to invest; confirm the current process directly. The cover is an illustrative ecosystem, not a literal map or an investor-network diagram.
Authored by Finta Editorial Team. Source review was AI-assisted; hypothetical examples are labelled illustrative and are not customer results.
Informational guidance
This content is for general informational and educational purposes, not personalized investment, financial, legal or tax advice. Finta is not a law firm. Consult your attorney or accountant about financing documents, eligibility, intellectual property, tax treatment and your company’s circumstances.